New immunosuppressive agents and risk for invasive fungal infections

Article

Abstract

Increased numbers of invasive fungal infections (IFI) were reported in patients treated with newer immunosuppressive drugs such as tumor necrosis factor (TNF)-α antagonists, the anti-CD52 antibody alemtuzumab, or the interleukin-2 receptor antibody basiliximab. These drugs are administered to patients who have autoimmune inflammatory diseases and lymphoid malignancies, or are recipients of solid organ or allogeneic hematopoietic stem cell transplants. IFI risk is higher in patients receiving TNF-α blockers or alemtuzumab late in the course of disease and in those with a history of IFI. Incidence and mortality rates of IFI are confounded by frequent, multiple comedications, heterogeneous definitions for IFI, and a presumed reporting bias. For filamentous molds and endemic fungal infections, different regional prevalence rates must be considered. Generally, invasive infections are more frequent among these groups and thus are important considerations in the management of patients receiving these immunosuppressive drugs.

References and Recommended Reading

  1. 1.
    Romani L: Immunity to fungal infections. Nat Rev Immunol 2004, 4:1–13.CrossRefPubMedGoogle Scholar
  2. 2.
    Segal BH: Aspergillosis. N Engl J Med 2009, 360:1870–1884.CrossRefPubMedGoogle Scholar
  3. 3.
    Shoham S, Levitz SM: The immune response to fungal infections. Br J Haematol 2005, 129:569–582.CrossRefPubMedGoogle Scholar
  4. 4.
    Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP: Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008, 83:181–194.CrossRefPubMedGoogle Scholar
  5. 5.
    Lundin J, Porwit-MacDonald A, Rossmann ED, et al.: Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004, 18:484–490.CrossRefPubMedGoogle Scholar
  6. 6.
    Brennan DC, Daller JA, Lake KD, et al.: Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006, 355:1967–1977.CrossRefPubMedGoogle Scholar
  7. 7.
    Chapman TM, Keating GM: Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs 2003, 63:2803–2835.CrossRefPubMedGoogle Scholar
  8. 8.
    Winthrop KL, Yamashita S, Beekmann SE, et al.: Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 2008, 46:1738–1740.CrossRefPubMedGoogle Scholar
  9. 9.
    Wallis RS, Broder MS, Wong JY, et al.: Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38:1261–1265.CrossRefPubMedGoogle Scholar
  10. 10.
    Wallis RS, Broder M, Wong J, Beenhouwer D: Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004, 39:1254–1255.CrossRefPubMedGoogle Scholar
  11. 11.
    Dixon WG, Watson K, Lunt M, et al.: Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54:2368–2376.CrossRefPubMedGoogle Scholar
  12. 12.
    Bongartz T, Sutton AJ, Sweeting MJ, et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275–2285.CrossRefPubMedGoogle Scholar
  13. 13.
    Listing J, Strangfeld A, Kary S, et al.: Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005, 52:3403–3412.CrossRefPubMedGoogle Scholar
  14. 14.
    Marty FM, Lee SJ, Fahey MM, et al.: Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003, 102:2768–2776.CrossRefPubMedGoogle Scholar
  15. 15.
    Couriel D, Saliba R, Hicks K, et al.: Tumor necrosis factoralpha blockade for the treatment of acute GVHD. Blood 2004, 104:649–654.CrossRefPubMedGoogle Scholar
  16. 16.
    Keating MJ, Flinn I, Jain V, et al.: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99:3554–3561.CrossRefPubMedGoogle Scholar
  17. 17.
    Thursky KA, Worth LJ, Seymour JF, et al.: Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006, 132:3–12.CrossRefPubMedGoogle Scholar
  18. 18.
    Dilhuydy MS, Jouary T, Demeaux H, Ravaud A: Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemia. Br J Haematol 2007, 137:490.CrossRefPubMedGoogle Scholar
  19. 19.
    Wendtner CM, Ritgen M, Schweighofer CD, et al.: Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004, 18:1093–1101.CrossRefPubMedGoogle Scholar
  20. 20.
    Lundin J, Kimby E, Bjorkholm M, et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia. Blood 2002, 100:768–773.CrossRefPubMedGoogle Scholar
  21. 21.
    Peleg AY, Husain S, Kwak EJ, et al.: Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007, 44:204–212.CrossRefPubMedGoogle Scholar
  22. 22.
    Silveira FP, Marcos A, Kwak EJ, et al.: Bloodstream infections in organ transplant recipients receiving alemtuzumab: no evidence of occurrence of organisms typically associated with profound T cell depletion. J Infect 2006, 53:241–247.CrossRefPubMedGoogle Scholar
  23. 23.
    Malek SK, Obmann MA, Gotoff RA, et al.: Campath-1H induction and the incidence of infectious complications in adult renal transplantation. Transplantation 2006, 81:17–20.CrossRefPubMedGoogle Scholar
  24. 24.
    Kahan BD, Rajagopalan PR, Hall M: Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 1999, 67:276–284.CrossRefPubMedGoogle Scholar
  25. 25.
    Alangaden GJ, Thyagarajan R, Gruber SA, et al.: Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant 2006, 20:401–409.CrossRefPubMedGoogle Scholar
  26. 26.
    Clinckart F, Bulpa P, Jamart J, et al.: Basiliximab as an alternative to antithymocyte globulin for early immunosuppression in lung transplantation. Transplant Proc 2009, 41:607–609.CrossRefPubMedGoogle Scholar
  27. 27.
    Ponticelli C, Yussim A, Cambi V, et al.: A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001, 72:1261–1267.CrossRefPubMedGoogle Scholar
  28. 28.
    Gruttadauria S, Vasta F, Mandala L, et al.: Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. Transplant Proc 2005, 37:2611–2613.CrossRefPubMedGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Department of Hematology, Oncology, and Palliative CareKlinikum Ernst von BergmannPotsdamGermany

Personalised recommendations